department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Praluent · pharmadog

pharmadog
drugs
Praluent

drug

patient view →

alirocumab

Marketedupdated 2mo ago

by Sanofi-Aventis US LLC

Approved

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 6 investigational indications.

indications

investigational

Hyperlipidemia

all catalysts(14)

approval · 14

view all 14 catalysts →

News(3)

Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
biopharma_dive · 2mo ago
STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House
stat · 2mo ago
STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
A deal with Regeneron was the last of 17 initially sought by the White House.
stat · 2mo ago

brand

Praluent

generic

alirocumab

MOA

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (LDL) receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.

indication

Heterozygous Familial Hypercholesterolemia (heFH)

phase

marketed

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

$REGN649.81-0.68%

🐶 often sniffed alongside

top 2

drugPRALUENT56 co-mentions · 14 sources
tagApproval56 co-mentions · 14 sources

Trials studying alirocumab

phase2A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemiarecruitingn=420
—Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)active not recruitingn=2,214
phase2PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lungactive not recruitingn=60
phase2TOP 2301: Neoadjuvant Chemo for NSCLCsuspendedn=126
—Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russiarecruitingn=2,382
phase1Alirocumab in Patients with Sepsiscompletedn=50
—Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patientsrecruitingn=10,000